Diarrhea in Breast Cancer
common.study.values.description
“An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide”
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Loperamide or other prophylactic measures.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Neratinib
Drug - Loperamide
Drug - Colestipol
2 g twice daily with or without food for one 28 day cycle
Drug - Budesonide
9 mg extended release tablets once daily with or without food for 28 days
participant.views.study.view.additional
participant.views.study.view.scientific-title
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
common.study.values.clinical-trial-id
NCT02400476
participant.views.study.view.id
7axoze
